268 related articles for article (PubMed ID: 34619493)
1. Targeting protein arginine methyltransferase 5 in cancers: Roles, inhibitors and mechanisms.
Chen Y; Shao X; Zhao X; Ji Y; Liu X; Li P; Zhang M; Wang Q
Biomed Pharmacother; 2021 Dec; 144():112252. PubMed ID: 34619493
[TBL] [Abstract][Full Text] [Related]
2. Protein arginine methyltransferase 5: a potential cancer therapeutic target.
Yuan Y; Nie H
Cell Oncol (Dordr); 2021 Feb; 44(1):33-44. PubMed ID: 33469838
[TBL] [Abstract][Full Text] [Related]
3. Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
Wang Y; Hu W; Yuan Y
J Med Chem; 2018 Nov; 61(21):9429-9441. PubMed ID: 29870258
[TBL] [Abstract][Full Text] [Related]
4. Targeting protein arginine methyltransferase 5 in disease.
Richters A
Future Med Chem; 2017 Nov; 9(17):2081-2098. PubMed ID: 29076773
[TBL] [Abstract][Full Text] [Related]
5. Medicinal chemistry strategies targeting PRMT5 for cancer therapy.
Fu S; Zheng Q; Zhang D; Lin C; Ouyang L; Zhang J; Chen L
Eur J Med Chem; 2022 Dec; 244():114842. PubMed ID: 36274274
[TBL] [Abstract][Full Text] [Related]
6. Role of protein arginine methyltransferase 5 in human cancers.
Xiao W; Chen X; Liu L; Shu Y; Zhang M; Zhong Y
Biomed Pharmacother; 2019 Jun; 114():108790. PubMed ID: 30903920
[TBL] [Abstract][Full Text] [Related]
7. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
Zhang B; Dong S; Zhu R; Hu C; Hou J; Li Y; Zhao Q; Shao X; Bu Q; Li H; Wu Y; Cen X; Zhao Y
Oncotarget; 2015 Sep; 6(26):22799-811. PubMed ID: 26078354
[TBL] [Abstract][Full Text] [Related]
8. The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer.
Quiroz RV; Reutershan MH; Schneider SE; Sloman D; Lacey BM; Swalm BM; Yeung CS; Gibeau C; Spellman DS; Rankic DA; Chen D; Witter D; Linn D; Munsell E; Feng G; Xu H; Hughes JME; Lim J; Saurí J; Geddes K; Wan M; Mansueto MS; Follmer NE; Fier PS; Siliphaivanh P; Daublain P; Palte RL; Hayes RP; Lee S; Kawamura S; Silverman S; Sanyal S; Henderson TJ; Ye Y; Gao Y; Nicholson B; Machacek MR
J Med Chem; 2021 Apr; 64(7):3911-3939. PubMed ID: 33755451
[TBL] [Abstract][Full Text] [Related]
9. Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5.
Zhang B; Zhang S; Zhu L; Chen X; Zhao Y; Chao L; Zhou J; Wang X; Zhang X; Ma N
Toxicol Appl Pharmacol; 2017 Dec; 336():1-7. PubMed ID: 28987382
[TBL] [Abstract][Full Text] [Related]
10. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
[TBL] [Abstract][Full Text] [Related]
11. Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies.
Zheng J; Li B; Wu Y; Wu X; Wang Y
J Med Chem; 2023 Jul; 66(13):8407-8427. PubMed ID: 37366223
[TBL] [Abstract][Full Text] [Related]
12. Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases.
Prabhu L; Chen L; Wei H; Demir Ö; Safa A; Zeng L; Amaro RE; O'Neil BH; Zhang ZY; Lu T
Mol Biosyst; 2017 Nov; 13(12):2509-2520. PubMed ID: 29099132
[TBL] [Abstract][Full Text] [Related]
13. Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
Sloan SL; Renaldo KA; Long M; Chung JH; Courtney LE; Shilo K; Youssef Y; Schlotter S; Brown F; Klamer BG; Zhang X; Yilmaz AS; Ozer HG; Valli VE; Vaddi K; Scherle P; Alinari L; Kisseberth WC; Baiocchi RA
PLoS One; 2021; 16(5):e0250839. PubMed ID: 33989303
[TBL] [Abstract][Full Text] [Related]
14. A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression.
Chen H; Lorton B; Gupta V; Shechter D
Oncogene; 2017 Jan; 36(3):373-386. PubMed ID: 27270440
[TBL] [Abstract][Full Text] [Related]
15. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
[No Abstract] [Full Text] [Related]
16. Research Progress on Small-molecule Inhibitors of Protein Arginine Methyltransferase 5 (PRMT5) for Treating Cancer.
Guo C; Wu L; Zheng X; Zhao L; Hou X; Wang Z; Han C
Curr Top Med Chem; 2023; 23(21):2048-2074. PubMed ID: 37438905
[TBL] [Abstract][Full Text] [Related]
17. Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.
Zhu K; Song JL; Tao HR; Cheng ZQ; Jiang CS; Zhang H
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3693-3699. PubMed ID: 30366617
[TBL] [Abstract][Full Text] [Related]
18. Protein arginine methyltransferase 5 catalyzes substrate dimethylation in a distributive fashion.
Wang M; Fuhrmann J; Thompson PR
Biochemistry; 2014 Dec; 53(50):7884-92. PubMed ID: 25485739
[TBL] [Abstract][Full Text] [Related]
19. Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies.
Abumustafa W; Zamer BA; Khalil BA; Hamad M; Maghazachi AA; Muhammad JS
Biomed Pharmacother; 2022 Jan; 145():112368. PubMed ID: 34794114
[TBL] [Abstract][Full Text] [Related]
20. Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4α.
Zheng BN; Ding CH; Chen SJ; Zhu K; Shao J; Feng J; Xu WP; Cai LY; Zhu CP; Duan W; Ding J; Zhang X; Luo C; Xie WF
Theranostics; 2019; 9(9):2606-2617. PubMed ID: 31131056
[No Abstract] [Full Text] [Related]
[Next] [New Search]
